Clinical Trials

On this site you will find a brief description of the clinical trials that are currently available or have been conducted through our office. We are continually going through the process to have more trials approved. If you have any questions about them or whether or not you might be a candidate feel free to contact us. alex@canceradvice.com

Study: T-Cell

Title: A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride Use. Closed to accrual.

Study: B-Cell

Title: A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-Cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride. Closed to accrual.

Study: PANVAC

Title: A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC-VF in Combination with GM-CSF Versus Best Supportive Care of Palliative Care or Palliative Chemotherapy in Patients with Metastasis (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regime. Closed to accrual.

Study: GVAX

Title: A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve. Closed to accrual.

Study: APRiCOT-P

This study is a randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the efficacy and safety of Apricoxib in combination with Gemcitabine and Erlotinib in the treatment of patients with advanced pancreatic cancer. Approximately 70 to 80 patients will be enrolled in this study at approximately 15 to 25 centers. The study treatment schedule includes an initial 56 day cycle to be followed by 28 day cycles which may be continued as determined by the Investigator until disease progression or intolerable toxicity.
Status: Open to accrual.

Captavi QixSuite™ - Hosted Marketing Automation Software ©